ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Nurse Practitioner

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,750Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 54

$698K Total Retail Price of All Prescriptions

Rank: 1 out of 54

260 Patients Receiving at Least One Drug in Part D
68% Patients 65 Years and Older
83% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in New Hampshire
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

12% of this provider’s 260 patients filled at least one prescription for a schedule two drug, compared to an average of 19%.

Schedule Three
Controlled Substances

8% of this provider’s 260 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$72 was the average price of a prescription from this provider, compared to $81 among peers.

Prescriptions per Patient

38 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in New Hampshire
SIMVASTATIN 359 274 52 1 8
CLOZAPINE 358 72 16 A 2 26
FUROSEMIDE 325 296 37 3 16
WARFARIN SODIUM 271 236 20 4 18
OMEPRAZOLE 258 173 43 5 10
LEVOTHYROXINE SODIUM 204 133 29 6 2
LISINOPRIL 193 164 38 7 3
QUETIAPINE FUMARATE 188 132 15 A 8 22
METOPROLOL SUCCINATE 188 154 33 8 5
ESCITALOPRAM OXALATE 182 165 16 10 35
POLYETHYLENE GLYCOL 3350 179 99 26 11 48
METFORMIN HCL 176 120 22 12 23
GABAPENTIN 167 79 27 13 6
VENLAFAXINE HCL ER 159 118 12 14 39
GENERLAC 153 117 21 15 53
TRAZODONE HCL 151 77 20 16 27
ATORVASTATIN CALCIUM 150 122 27 17 4
TAMSULOSIN HCL 149 122 17 18 27
POTASSIUM CHLORIDE 149 117 20 18 56
ENULOSE 143 115 19 20 57
AMLODIPINE BESYLATE 142 124 26 21 12
LOSARTAN POTASSIUM 132 114 28 22 58
OLANZAPINE 119 <11 <11 A 23 24
FINASTERIDE 110 82 12 24 37
RISPERIDONE 108 <11 <11 A 25 40
SERTRALINE HCL 100 83 19 26 33
DIVALPROEX SODIUM 94 <11 <11 27 71
FAMOTIDINE* 92 54 16 28 73
LITHIUM CARBONATE 90 <11 <11 29 75
LEVETIRACETAM 86 <11 <11 30 50
CITALOPRAM HBR 83 60 12 31 46
MIRTAZAPINE 79 <11 <11 32 54
DOXAZOSIN MESYLATE 78 67 11 33 79
IPRATROPIUM-ALBUTEROL 75 30 19 34 81
TOPIRAMATE 75 <11 <11 34 34
ENOXAPARIN SODIUM 74 <11 <11 36 83
ATENOLOL 71 66* 13 37 51
LANTUS 66 <11 <11 38 88
CLOPIDOGREL 65 46 11 39 15
METOPROLOL TARTRATE 65 60* 17 39 29
BACLOFEN 63 <11 <11 41 36
DIVALPROEX SODIUM ER 62 <11 <11 42 91
CARBAMAZEPINE 62 <11 <11 42 91
PANTOPRAZOLE SODIUM 61 <11 <11 44 47
JANUVIA 57 <11 <11 45 97
ABILIFY 55 <11 <11 A 46 68
NAMENDA 53 <11 <11 47 102
CLONAZEPAM 53 14 11 B 47 17
ISOSORBIDE MONONITRATE ER 52 <11 <11 49 106
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 22, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.